Enhancing the effectiveness of standard-of-care treatments by integrating ALDH1A3 inhibitors for synergistic outcomes.
Pancreatic Cancer
Aiming to provide new therapeutic options for one of the most challenging cancers to treat due to its resistance to conventional therapies.
Glioblastoma
Developing innovative treatments for this aggressive brain cancer, with a focus on limiting tumor growth and improving quality of life.
Prostate Cancer
Tackling metastatic prostate cancer through ALDH1A3 inhibition to enhance treatment efficacy and reduce drug resistance.
Colorectal Cancer
Offering precision therapies to patients with advanced colorectal cancer, focusing on reducing recurrence rates.
Lung Cancer
Addressing chemotherapy-resistant non-small cell lung cancers by inhibiting ALDH1A3-driven tumor progression.
Breast Cancer
Targeting aggressive forms of breast cancer with high ALDH1A3 expression to reduce metastasis and improve survival outcomes.